PHAXIAM THERAPEUTICS S.A.

Highlights PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Market Closed - Euronext Paris Other stock markets 13:38:02 08/05/2024 BST			5-day change	1st Jan Change
2.94 ^EUR	+1.38%		-0.68%	-36.09%

04-15	Phaxiam initiates trial in infective endocarditis	CF
04-15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phaxiam initiates trial in infective endocarditis	04-15	CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	04-15	CI
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq	03-11	MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	02-21
Phaxiam to delist ADS from Nasdaq in March	02-21	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer